Clinical trial · Interventional
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin
NCT00006864CI-TRIAL-00013366completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven metastatic renal cell carcinoma * Clear cell * Papillary * Sarcomatoid * Mixed * Measurable or evaluable disease * Evidence of disease following surgical resection of metastases * No CNS disease PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 60-100% Life expectancy: * Not specified Hematopoietic: * Hemoglobin at least 10 g/dL * WBC at least 4,000/mm3 * Platelet count at least 100,000/mm3 Hepatic: * Not specified Renal: * Creatinine no greater than 1.8 mg/dL Cardiovascular: * No New York Heart Association class III or IV heart disease Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception (barrier plus 1 other method) * Thyroid-stimulating hormone normal * No known hypersensitivity or allergy to components of recombinant human interleukin-2 * No known autoimmune disease (e.g., Crohn's disease) * No other concurrent medical condition that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior recombinant human interleukin-2 * No concurrent interferon alfa Chemotherapy: * No concurrent cytoxic chemotherapy Endocrine therapy: * No concurrent hormonal therapy (e.g., medroxyprogesterone) other than estrogen replacement therapy * No concurrent prophylactic glucocorticoids (replacement doses and topical use allowed) * No concurrent systemic corticosteroids Radiotherapy: * At least 4 weeks since prior radiotherapy * No prior radiotherapy to index lesion * No concurrent radiotherapy Surgery: * See Disease Characteristics * Prior surgery for renal cell carcinoma allowed Other: * No prior systemic therapy for renal cell carcinoma * At least 4 weeks since prior investigational drugs * No other concurrent investigational drugs or participation in another clinical study * No concurrent iodinated radiocontrast dye * No concurrent drugs for another indication that has purported activity in treatment of neoplasia (e.g., thalidomide)
References
Publications (0)
Data not yet available
No reference posted for this study.